reviewTop 1% cited
Herceptin: mechanisms of action and resistance
Cancer Letters · 2005 · Vol. 232(2) · pp. 123–138
Rita Nahta(The University of Texas MD Anderson Cancer Center)Francisco J. Esteva✉(The University of Texas MD Anderson Cancer Center)
HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchCell Adhesion Molecules ResearchMedicineBreast cancerTrastuzumabOncologyChemotherapyCancer researchInternal medicineTargeted therapyCancerImmunology
MeSH terms
TrastuzumabAnimalsAntibodies, MonoclonalAntineoplastic AgentsClinical Trials as TopicDNA RepairHumansSignal TransductionApoptosisErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-2Drug Resistance, NeoplasmAngiogenesis InhibitorsCyclin-Dependent Kinase Inhibitor p27Antibodies, Monoclonal, Humanized
Citations
440
FWCI
11.90
field-weighted impact
References
156
Percentile
99%
vs. same field & year
Citations per year
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Angewandte Chemie International Edition · 2014 · 2,114 citations
References
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
The EMBO Journal · 1997 · 1,569 citations
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Cancer Cell · 2004 · 1,856 citations
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Journal of Clinical Oncology · 2002 · 2,949 citations
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Nature Medicine · 2000 · 2,723 citations
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
Science · 1987 · 11,680 citations
HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression
Molecular and Cellular Biology · 2001 · 1,245 citations
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Journal of Clinical Oncology · 1999 · 2,788 citations
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science · 2004 · 9,380 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.